Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) was downgraded by equities researchers at ValuEngine from a “sell” rating to a “strong sell” rating in a report released on Friday, June 2nd.

Several other research analysts also recently weighed in on ANTH. Jefferies Group LLC dropped their target price on Anthera Pharmaceuticals from $8.00 to $6.40 and set a “hold” rating on the stock in a research note on Monday, March 6th. Zacks Investment Research upgraded Anthera Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $6.00 target price on the stock in a research note on Wednesday, March 8th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $10.21.

Analyst Recommendations for Anthera Pharmaceuticals (NASDAQ:ANTH)

Shares of Anthera Pharmaceuticals (NASDAQ:ANTH) traded up 0.62% during trading on Friday, hitting $1.62. The company had a trading volume of 73,682 shares. The company’s 50 day moving average is $1.66 and its 200 day moving average is $1.04. Anthera Pharmaceuticals has a 1-year low of $1.54 and a 1-year high of $32.00. The firm’s market capitalization is $16.32 million.

Anthera Pharmaceuticals (NASDAQ:ANTH) last announced its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($2.03) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.47) by $0.56. Analysts anticipate that Anthera Pharmaceuticals will post ($5.06) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Anthera Pharmaceuticals, Inc. (ANTH) Downgraded by ValuEngine to “Strong Sell”” was posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/06/13/anthera-pharmaceuticals-inc-anth-downgraded-by-valuengine-to-strong-sell.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Abingworth LLP increased its position in shares of Anthera Pharmaceuticals by 16.9% in the third quarter. Abingworth LLP now owns 512,036 shares of the biopharmaceutical company’s stock valued at $1,531,000 after buying an additional 74,042 shares during the period. Vanguard Group Inc. increased its position in shares of Anthera Pharmaceuticals by 49.1% in the first quarter. Vanguard Group Inc. now owns 2,691,639 shares of the biopharmaceutical company’s stock valued at $1,145,000 after buying an additional 886,910 shares during the period. Geode Capital Management LLC increased its position in shares of Anthera Pharmaceuticals by 16.2% in the first quarter. Geode Capital Management LLC now owns 355,172 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 49,391 shares during the period. UBS Group AG increased its position in shares of Anthera Pharmaceuticals by 9.9% in the first quarter. UBS Group AG now owns 375,989 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 33,901 shares during the period. Finally, Sabby Management LLC increased its position in shares of Anthera Pharmaceuticals by 1,809.7% in the first quarter. Sabby Management LLC now owns 1,757,697 shares of the biopharmaceutical company’s stock valued at $748,000 after buying an additional 1,665,655 shares during the period.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.